Kyowa's BioWa Inc. subsidiary granted arGEN-X non-exclusive rights to use its Potelligent ADCC technology to develop arGEN-X's mAbs for cancer and inflammatory disorders

Kyowa Hakko Kirin Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

argenx S.E.

the Netherlands / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced